Anivive's Pivotal Study Marks Progress for Canine Lymphoma Treatment Anivive has announced the completion of a significant pivotal study for LAVERDIA®-CA1, a groundbreaking treatment for canine lymphoma, paving the way for FDA approval.

Anivive's Pivotal Study Marks Progress for Canine Lymphoma Treatment #United_States #Long_Beach #Canine_Lymphoma #Anivive #LAVERDIA